Premal D Lulla - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Premal D Lulla

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Blood|February 8, 2022

Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALLSwati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.

Blood|March 24, 2022

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.

Transplantation and Cellular Therapy|April 27, 2025

Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.

Blood Advances|August 14, 2025

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Blood|February 8, 2022

Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALLSwati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.

Blood|March 24, 2022

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.

Transplantation and Cellular Therapy|April 27, 2025

Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.

Blood Advances|August 14, 2025

New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.

Pageof 2